Pharma BD Deal Intelligence
Not an acquisition at all — a small $685M option/license deal for one preclinical antibody, and the asset it bought (livmoniplimab) has since flopped in the clinic while argenx itself became an independent ~$40B blockbuster company AbbVie never owned.
Full analysis, sources & comparables →AbbVie and argenx announced a collaboration to develop and commercialize ARGX-115, a novel therapeutic candidate targeting GARP, providing argenx an upfront…
AbbVie exercised its exclusive option to license ARGX-115 following completion of IND-enabling studies, validating the 2016 collaboration and triggering…
Analysts characterized AbbVie's Phase 3 acceleration of livmoniplimab as 'on a wing and a prayer' given monotherapy zero responses and 12% combination ORR,…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
AbbVie and argenx entered a collaboration for ARGX-115 (ABBV-151), a preclinical anti-GARP cancer immunotherapy. AbbVie paid $40M upfront plus up to $20M near-term preclinical milestones. argenx eligible for up to $625M in additional development, regulatory, and commercial milestones plus tiered double-digit royalties. AbbVie also received option to license additional immune checkpoint targets.
Not an acquisition at all — a small $685M option/license deal for one preclinical antibody, and the asset it bought (livmoniplimab) has since flopped in the clinic while argenx itself became an independent ~$40B blockbuster company AbbVie never owned.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / argenx SE (this deal) | 2016 | $685M | 25 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2016 deals · AbbVie Inc. deals · Oncology deals